Third-Generation Trabecular Micro-Bypass Implantation with Phacoemulsification for Glaucoma

Area of Science:

• Ophthalmology
• Glaucoma Surgery
• Medical Devices

Background:

• Assessed real-world efficacy and safety of iStent infinite implantation with phacoemulsification.
• Focused on patients with mild-to-moderate primary open-angle glaucoma (POAG).

Purpose of the Study:

• Evaluate the effectiveness of iStent infinite in reducing intraocular pressure (IOP) and medication burden.
• Assess the safety profile and need for secondary procedures post-implantation.

Main Methods:

• Retrospective case series of 121 eyes undergoing phacoemulsification and iStent infinite implantation.
• Monitored IOP, medication use, and adverse events over 12 months.
• Analyzed data for both observed and consistent cohorts.

Main Results:

• Mean IOP reduced by 23.8% (18.1 to 13.8 mmHg) and medication use by 23.2% at 12 months (p<0.001).
• Proportions achieving target IOP (≤18/15/12 mmHg) significantly increased.
• Adverse events were mostly mild; <3% required secondary glaucoma interventions.

Conclusions:

• iStent infinite combined with cataract surgery provides significant IOP and medication reduction.
• Demonstrates favorable safety and efficacy in a real-world setting.
• Represents one of the largest published datasets for this device in combination with cataract surgery.